TY - JOUR
T1 - Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
AU - Fusaroli, Michele
AU - Polizzi, Stefano
AU - Menestrina, Luca
AU - Giunchi, Valentina
AU - Pellegrini, Luca
AU - Raschi, Emanuel
AU - Weintraub, Daniel
AU - Recanatini, Maurizio
AU - Castellani, Gastone
AU - De Ponti, Fabrizio
AU - Poluzzi, Elisabetta
N1 - © 2024 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc/4.0/
PY - 2024/8/15
Y1 - 2024/8/15
N2 - Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.
AB - Impulsivity induced by dopaminergic agents, like pramipexole and aripiprazole, can lead to behavioral addictions that impact on social functioning and quality of life of patients and families (e.g., resulting in unemployment, marital problems, anxiety). These secondary effects, interconnected in networks of signs and symptoms, are usually overlooked by clinical trials, not reported in package inserts, and neglected in clinical practice.
U2 - 10.1007/s40264-024-01471-z
DO - 10.1007/s40264-024-01471-z
M3 - Article
SN - 1179-1942
JO - Drug Safety
JF - Drug Safety
ER -